Endocrinology and Metabolism

Young Min Cho (Cho YM)

26 Articles

Diabetes, obesity and metabolism
Ketonuria as an Indicator of Improvement of Renal Function in Patients with Type 2 Diabetes Receiving SGLT2 Inhibitor Treatment: Hyun Ah Kim, Han Na Jang, Sung Hye Kong, Young Lee, Sung Hee Choi, Young Min Cho, Hak Chul Jang, Tae Jung Oh; Endocrinol Metab. 2024;39(4):653-658. Published online May 16, 2024; DOI: https://doi.org/10.3803/EnM.2024.1919

1,620 View
100 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

We investigated the potential association between ketonuria during treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors and its renoprotective effect in patients with type 2 diabetes. We included 192 patients who had received SGLT2 inhibitors for more than 6 months. After propensity score matching, 52 patients each were allocated into groups with or without ketonuria, respectively. The estimated glomerular filtration rate exhibited a significant improvement only in subjects with ketonuria (without ketonuria: mean difference, –0.02 mL/min/1.73 m² [95% confidence interval (CI), –3.87 to 3.83 mL/min/1.73 m²] vs. with ketonuria: mean difference, 6.81 mL/min/1.73 m² [95% CI, 3.16 to 10.46 mL/min/1.73 m²]; P<0.001). Improvement in estimated glomerular filtration rate at 6 months was associated with female sex and lower baseline body weight, blood pressure, and triglyceride levels in patients with ketonuria. In conclusion, the presence of ketonuria was associated with the renoprotective effect of SGLT2 inhibitors, and female sex and the absence of metabolic syndrome components may serve as additional indicators of these medications’ substantial renoprotective effects in individuals with ketonuria.

Citations

Citations to this article as recorded by

Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression
Melina Messing, Jacob A. Torres, Nickolas Holznecht, Thomas Weimbs
Nutrients.2024; 16(19): 3281. CrossRef

Diabetes, obesity and metabolism
Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease: Hun Jee Choe, Yeh-Hee Ko, Sun Joon Moon, Chang Ho Ahn, Kyoung Hwa Ha, Hyeongsuk Lee, Jae Hyun Bae, Hyung Joon Joo, Hyejin Lee, Jang Wook Son, Dae Jung Kim, Sin Gon Kim, Kwangsoo Kim, Young Min Cho; Endocrinol Metab. 2024;39(4):622-631. Published online August 1, 2024; DOI: https://doi.org/10.3803/EnM.2024.1965

1,099 View
46 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Dipeptidyl peptidase-4 (DPP4) inhibitors are frequently prescribed for patients with type 2 diabetes; however, their cost can pose a significant barrier for those with impaired kidney function. This study aimed to estimate the economic benefits of substituting non-renal dose-adjusted (NRDA) DPP4 inhibitors with renal dose-adjusted (RDA) DPP4 inhibitors in patients with both impaired kidney function and type 2 diabetes.
Methods
This retrospective cohort study was conducted from January 1, 2012 to December 31, 2018, using data obtained from common data models of five medical centers in Korea. Model 1 applied the prescription pattern of participants with preserved kidney function to those with impaired kidney function. In contrast, model 2 replaced all NRDA DPP4 inhibitors with RDA DPP4 inhibitors, adjusting the doses of RDA DPP4 inhibitors based on individual kidney function. The primary outcome was the cost difference between the two models.
Results
In total, 67,964,996 prescription records were analyzed. NRDA DPP4 inhibitors were more frequently prescribed to patients with impaired kidney function than in those with preserved kidney function (25.7%, 51.3%, 64.3%, and 71.6% in patients with estimated glomerular filtration rates [eGFRs] of ≥60, <60, <45, and <30 mL/min/1.73 m², respectively). When model 1 was applied, the cost savings per year were 7.6% for eGFR <60 mL/min/1.73 m² and 30.4% for eGFR <30 mL/min/1.73 m². According to model 2, 15.4% to 51.2% per year could be saved depending on kidney impairment severity.
Conclusion
Adjusting the doses of RDA DPP4 inhibitors based on individual kidney function could alleviate the economic burden associated with medical expenses.

Diabetes, Obesity and Metabolism
Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes: Chang Ho Ahn, Tae Jung Oh, Se Hee Min, Young Min Cho; Endocrinol Metab. 2023;38(1):1-9. Published online February 13, 2023; DOI: https://doi.org/10.3803/EnM.2023.103

4,465 View
403 Download
3 Web of Science
5 Crossref

Abstract PDF PubReader ePub

To maintain normal glucose homeostasis after a meal, it is essential to secrete an adequate amount of insulin from pancreatic β-cells. However, if pancreatic β-cells solely depended on the blood glucose level for insulin secretion, a surge in blood glucose levels would be inevitable after the ingestion of a large amount of carbohydrates. To avoid a deluge of glucose in the bloodstream after a large carbohydrate- rich meal, enteroendocrine cells detect the amount of nutrient absorption from the gut lumen and secrete incretin hormones at scale. Since insulin secretion in response to incretin hormones occurs only in a hyperglycemic milieu, pancreatic β-cells can secrete a “Goldilocks” amount of insulin (i.e., not too much and not too little) to keep the blood glucose level in the normal range. In this regard, pancreatic β-cell sensitivity to glucose and incretin hormones is crucial for maintaining normal glucose homeostasis. In this Namgok lecture 2022, we review the effects of current anti-diabetic medications on pancreatic β-cell sensitivity to glucose and incretin hormones.

Citations

Citations to this article as recorded by

Initial Combination Therapy in Type 2 Diabetes
Ji Yoon Kim, Nam Hoon Kim
Endocrinology and Metabolism.2024; 39(1): 23. CrossRef
Impact of Some Natural and Artificial Sweeteners Consumption on Different Hormonal Levels and Inflammatory Cytokines in Male Rats: In Vivo and In Silico Studies
Dina Mostafa Mohammed, Mohamed A. Abdelgawad, Mohammed M. Ghoneim, Abdulaziz Alhossan, Rasha Hamed Al-Serwi, Amr Farouk
ACS Omega.2024; 9(28): 30364. CrossRef
Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations
Muthanna K. Zaki, Mohammed N. Abed, Fawaz A. Alassaf
Journal of Bone Metabolism.2024; 31(3): 169. CrossRef
GHRH in diabetes and metabolism
Charlotte Steenblock, Stefan R. Bornstein
Reviews in Endocrine and Metabolic Disorders.2024;[Epub] CrossRef
Recent Glycemia Is a Major Determinant of β-Cell Function in Type 2 Diabetes Mellitus
Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2024; 48(6): 1135. CrossRef

Miscellaneous
In Memoriam: Remembering Professor Hun-Ki Min (1928–2021): Young Min Cho; Endocrinol Metab. 2021;36(2):207-208. Published online April 20, 2021; DOI: https://doi.org/10.3803/EnM.2021.204

3,433 View
158 Download

PDF PubReader ePub

Diabetes
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists: Hun Jee Choe, Young Min Cho; Endocrinol Metab. 2021;36(1):22-29. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2021.102

29,796 View
727 Download
18 Web of Science
19 Crossref

Abstract PDF PubReader ePub

Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering medications with salient benefits for body weight and cardiovascular events. This class of medications is now recommended as the top priority for patients with established cardiovascular disease or indicators of high risk. Until the advent of oral semaglutide, however, GLP-1 receptor agonists were available only in the form of subcutaneous injections. Aversion to needles, discomfort with self-injection, or skin problems at the injection site are commonly voiced problems in people with diabetes, and thus, attempts for non-invasive delivery strategies have continued. Herein, we review the evolution of GLP-1 therapy from its discovery and the development of currently approved drugs to the unprecedented endeavor to administer GLP-1 receptor agonists via the oral route. We focus on the pharmacokinetic and pharmacodynamic properties of the recently approved oral GLP-1 receptor agonist, oral semaglutide. Small molecule oral GLP-1 receptor agonists are currently in development, and we introduce how these chemicals have addressed the challenge posed by interactions with the large extracellular ligand binding domain of the GLP-1 receptor. We specifically discuss the structure and pharmacological properties of TT-OAD2, LY3502970, and PF-06882961, and envision an era where more patients could benefit from oral GLP-1 receptor agonist therapy.

Citations

Citations to this article as recorded by

Sulfobetaine modification of poly (D, L-lactide-co-glycolic acid) nanoparticles enhances mucus permeability and improves bioavailability of orally delivered liraglutide
Zhenyu Zhao, Ruihuan Ding, Yumei Wang, Ranran Yuan, Houqian Zhang, Tianyang Li, Wei Zheng, Entao Chen, Aiping Wang, Yanan Shi
Journal of Drug Delivery Science and Technology.2024; 93: 105437. CrossRef
Physiology and pharmacology of glucagon-like peptide-1 receptor
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, V. I. Petrov, A. V. Strygin, K. N. Koryanova, Yu. V. Gorbunova, Yu. A. Kolosov, O. V. Ivanova, E. V. Pavlova, M. A. Dzhavakhyan, A. V. Zaborovsky, V. B. Saparova, I. E. Makarenko, R. I. Drai, A. N. Chumachenko
Pharmacy & Pharmacology.2024; 11(4): 347. CrossRef
G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
Mohan Patil, Ilaria Casari, Leon N. Warne, Marco Falasca
Biomedicine & Pharmacotherapy.2024; 172: 116245. CrossRef
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Binbin Gong, Zhihong Yao, Chenxu Zhou, Wenxi Wang, Lidan Sun, Jing Han
European Journal of Medicinal Chemistry.2024; 269: 116342. CrossRef
The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
Haowen Fang, Bing Niu, Qin Chen
Current Medicinal Chemistry.2024; 31(20): 2921. CrossRef
Binding sites and design strategies for small molecule GLP-1R agonists
Haibo Zhang, Tianxiao Wu, Yong Wu, Yuran Peng, Xian Wei, Tao Lu, Yu Jiao
European Journal of Medicinal Chemistry.2024; 275: 116632. CrossRef
Advances in small-molecule insulin secretagogues for diabetes treatment
Jingqian Su, Jingran Xu, Shan Hu, Hui Ye, Lian Xie, Songying Ouyang
Biomedicine & Pharmacotherapy.2024; 178: 117179. CrossRef
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
Zhiqiang Ke, Qianqian Ma, Xiaonan Ye, Yanlin Wang, Yan Jin, Xinyuan Zhao, Zhengding Su
Biochemical Pharmacology.2024; 229: 116471. CrossRef
Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor
Zhimin Zhang, Hao Pan, Liubin Guo, Cancan Cai, Tingni Chen, Zhiping Zhang, Xu Yang, Haowen Zheng, Chunhua Jiang, Zhiyong Wang, Yacheng Yang, Zhe Wang, Xiaohua Zhang, Yuchen Zhang, Dongzhou Liu
Journal of Medicinal Chemistry.2024; 67(17): 14820. CrossRef
Toxicology profile of a novel GLP-1 receptor biased agonist-SAL0112 in nonhuman primates
Jingchao Sun, Ying Xiao, Xuefeng Hu, Shu Chen, Jing Huang, Zhiqiang Ren, Binbin Luo, Rongzhi Jiang, Hongmei Zhang, Xiaolei Shen
Toxicology and Applied Pharmacology.2024; 492: 117125. CrossRef
Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang, Jincheng Wang
Acta Pharmaceutica Sinica B.2023; 13(6): 2383. CrossRef
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Shurui Hong, J. Xiao, Y. He
BIO Web of Conferences.2023; 61: 01006. CrossRef
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Panagiotis Stachteas, Konstantinos I. Bougioukas, Aleksandra Klisic, Nikolaos Fragakis, Manfredi Rizzo
Metabolism.2023; 149: 155710. CrossRef
A review of glucoregulatory hormones potentially applicable to the treatment of Alzheimer’s disease: mechanism and brain delivery
Reeju Amatya, Kyoung Ah Min, Meong Cheol Shin
Journal of Pharmaceutical Investigation.2022; 52(2): 195. CrossRef
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold E. Bays, Angela Fitch, Sandra Christensen, Karli Burridge, Justin Tondt
Obesity Pillars.2022; 2: 100018. CrossRef
Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24
Zhaotong Cong, Qingtong Zhou, Yang Li, Li-Nan Chen, Zi-Chen Zhang, Anyi Liang, Qing Liu, Xiaoyan Wu, Antao Dai, Tian Xia, Wei Wu, Yan Zhang, Dehua Yang, Ming-Wei Wang
Proceedings of the National Academy of Sciences.2022;[Epub] CrossRef
Improved Split TEV GPCR β-arrestin-2 Recruitment Assays via Systematic Analysis of Signal Peptide and β-arrestin Binding Motif Variants
Yuxin Wu, Isabelle von Hauff, Niels Jensen, Moritz Rossner, Michael Wehr
Biosensors.2022; 13(1): 48. CrossRef
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao, Minghe Wang, Zhitong Wen, Zhihong Lu, Lijuan Cui, Chao Fu, Huan Xue, Yunfeng Liu, Yi Zhang
Frontiers in Endocrinology.2021;[Epub] CrossRef
Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class
Evie K. Bain, Stephen C. Bain
Diabetes, Obesity and Metabolism.2021; 23(S3): 30. CrossRef

Erratum: Correction of Figure. Clinical Implications of Various Criteria for the Biochemical Diagnosis of Insulinoma: Chang Ho Ahn, Lee-Kyung Kim, Jie Eun Lee, Chan-Hyeon Jung, Se-Hee Min, Kyong Soo Park, Seong Yeon Kim, Young Min Cho; Endocrinol Metab. 2017;32(2):306. Published online June 23, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.2.306

3,257 View
32 Download

PDF PubReader

Clinical Study
1,5-Anhydro-D-Glucitol Could Reflect Hypoglycemia Risk in Patients with Type 2 Diabetes Receiving Insulin Therapy: Min Kyeong Kim, Hye Seung Jung, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Seong Yeon Kim; Endocrinol Metab. 2016;31(2):284-291. Published online May 27, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.2.284

5,173 View
45 Download
6 Web of Science
7 Crossref

Abstract PDF PubReader

Background

The identification of a marker for hypoglycemia could help patients achieve strict glucose control with a lower risk of hypoglycemia. 1,5-Anhydro-D-glucitol (1,5-AG) reflects postprandial hyperglycemia in patients with well-controlled diabetes, which contributes to glycemic variability. Because glycemic variability is related to hypoglycemia, we aimed to evaluate the value of 1,5-AG as a marker of hypoglycemia.

Methods

We enrolled 18 adults with type 2 diabetes mellitus (T2DM) receiving insulin therapy and assessed the occurrence of hypoglycemia within a 3-month period. We measured 1,5-AG level, performed a survey to score the severity of hypoglycemia, and applied a continuous glucose monitoring system (CGMS).

Results

1,5-AG was significantly lower in the high hypoglycemia-score group compared to the low-score group. Additionally, the duration of insulin treatment was significantly longer in the high-score group. Subsequent analyses were adjusted by the duration of insulin treatment and mean blood glucose, which was closely associated with both 1,5-AG level and hypoglycemia risk. In adjusted correlation analyses, 1,5-AG was negatively correlated with hypoglycemia score, area under the curve at 80 mg/dL, and low blood glucose index during CGMS (P=0.068, P=0.033, and P=0.060, respectively).

Conclusion

1,5-AG level was negatively associated with hypoglycemia score determined by recall and with documented hypoglycemia after adjusting for mean glucose and duration of insulin treatment. As a result, this level could be a marker of the risk of hypoglycemia in patients with well-controlled T2DM receiving insulin therapy.

Citations

Citations to this article as recorded by

Neurological dysfunction screening in a cohort of adolescents with type 1 diabetes: a six-year follow-up
Davide Tinti, Carlotta Canavese, Cecilia Nobili, Daniele Marcotulli, Erika Daniele, Ivana Rabbone, Luisa de Sanctis
Frontiers in Medicine.2024;[Epub] CrossRef
The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications
Huijuan Xu, Junhua Pan, Qiu Chen
Frontiers in Endocrinology.2024;[Epub] CrossRef
Mobile Healthcare System Provided by Primary Care Physicians Improves Quality of Diabetes Care
Tae Jung Oh, Jie-Eun Lee, Seok Kim, Sooyoung Yoo, Hak Chul Jang
CardioMetabolic Syndrome Journal.2021; 1(1): 88. CrossRef
Effects of mobile phone application combined with or without self‐monitoring of blood glucose on glycemic control in patients with diabetes: A randomized controlled trial
Yuan Yu, Qun Yan, Huizhi Li, Hongmei Li, Lin Wang, Hua Wang, Yiyun Zhang, Lei Xu, Zhaosheng Tang, Xinfeng Yan, Yinghua Chen, Huili He, Jie Chen, Bo Feng
Journal of Diabetes Investigation.2019; 10(5): 1365. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
A Diet Diverse in Bamboo Parts is Important for Giant Panda (Ailuropoda melanoleuca) Metabolism and Health
Hairui Wang, Heju Zhong, Rong Hou, James Ayala, Guangmang Liu, Shibin Yuan, Zheng Yan, Wenping Zhang, Yuliang Liu, Kailai Cai, Zhigang Cai, He Huang, Zhihe Zhang, De Wu
Scientific Reports.2017;[Epub] CrossRef
Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention
Shuhei Takahashi, Kazunori Shimada, Katsumi Miyauchi, Tetsuro Miyazaki, Eiryu Sai, Manabu Ogita, Shuta Tsuboi, Hiroshi Tamura, Shinya Okazaki, Tomoyuki Shiozawa, Shohei Ouchi, Tatsuro Aikawa, Tomoyasu Kadoguchi, Hamad Al Shahi, Takuma Yoshihara, Makoto Hi
Cardiovascular Diabetology.2016;[Epub] CrossRef

Clinical Study
Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes: Se Hee Min, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Hye Seung Jung; Endocrinol Metab. 2015;30(4):509-513. Published online December 31, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.4.509

5,306 View
77 Download
3 Web of Science
2 Crossref

Abstract PDF PubReader

Background

Even though several oral anti-diabetic drugs (OAD) with various modes of action are replacing sulfonylurea (SU), some patients seem to be dependent on SU for adequate glycemic control. Therefore, we evaluated the clinical characteristics of such patients.

Methods

We selected the patients with type 2 diabetes who met following criteria from 2009 to 2014 at Seoul National University Hospital: glycated hemoglobin (HbA1c) was maintained below 7.5% for at least 6 months under small dose of SU (glimepiride ≤2 mg/day or equivalent dose); after discontinuation of SU, HbA1c increased ≥1.2% within 3 months or ≥1.5% within 6 months; and after resuming SU, HbA1c reduction was ≥0.8% or reduction of fasting plasma glucose was ≥40 mg/dL within 3 months. Patients with impaired hepatic or renal function, and steroid users were excluded.

Results

Nineteen subjects were enrolled: after averaged 4.8±1.5 months of SU-free period, HbA1c increased from 6.7%±0.4% to 8.8%±0.8% even though adding other OAD such as gliptins. However, HbA1c decreased to 7.4%±0.7% after resuming SU within 2.4±0.8 months. There was no sexual predominance. Despite their old age (67±11 years) and long duration of diabetes (18±10 years), fasting C-peptide was relatively well-reserved (3.9±2.6 ng/mL), and nephropathy was not observed (albumin-creatinine ratio 21.2±16.6 mg/g and estimated glomerular filtration rate 75.8±18.0 mL/min/1.73 m²). Strong family history was also noted (73.7%).

Conclusion

Despite hypoglycemia risk of SU, it seemed indispensable for a subset of patients with regard to insulin secretion. Genetic influences would be evaluated.

Citations

Citations to this article as recorded by

Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study
Ji-Yeon Lee, Suk-Yong Jang, Chung Mo Nam, Eun Seok Kang
Scientific Reports.2019;[Epub] CrossRef
A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
Eugene Han, Hye Sun Park, Obin Kwon, Eun Yeong Choe, Hye Jin Wang, Yong-ho Lee, Sang-Hak Lee, Chul Hoon Kim, Lee-Kyung Kim, Soo Heon Kwak, Kyong Soo Park, Chul Sik Kim, Eun Seok Kang
Medicine.2016; 95(44): e5155. CrossRef

Obesity and Metabolism
Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells: Mi Yeon Kang, Tae Jung Oh, Young Min Cho; Endocrinol Metab. 2015;30(2):216-220. Published online June 30, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.2.216

4,799 View
52 Download
46 Web of Science
44 Crossref

Abstract PDF PubReader

Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that increases glucose-stimulated insulin secretion in pancreatic β-cells. Since mitochondrial function is crucial to insulin secretion, we hypothesized that GLP-1 may increase mitochondrial biogenesis in pancreatic β-cells. We treated INS-1 rat insulinoma cells with GLP-1 or exendin-4 for 48 hours and measured mitochondrial mass and function. Both GLP-1 and exendin-4 increased mitochondrial mass by approximately 20%. The mitochondria/cytosol ratio was increased from 7.60±3.12% to 10.53±2.70% by exendin-4. In addition, GLP-1 increased the mitochondrial membrane potential and oxygen consumption. Proliferator-activated receptor-gamma coactivator 1α expression was increased approximately 2-fold by GLP-1 treatment. In conclusion, the present study presents evidence for a new mechanism of action by which GLP-1 improves pancreatic β-cell function via enhanced mitochondrial mass and performance.

Citations

Citations to this article as recorded by

New fraternine analogues: Evaluation of the antiparkinsonian effect in the model of Parkinson's disease
Andréia Biolchi Mayer, Henrique de Oliveira Amaral, Danilo Gustavo R. de Oliveira, Gabriel Avohay Alves Campos, Priscilla Galante Ribeiro, Solange Cristina Rego Fernandes, Adolfo Carlos Barros de Souza, Raffael Júnio Araújo de Castro, Anamélia Lorenzetti
Neuropeptides.2024; 103: 102390. CrossRef
Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
Lidan Hu, Wenmin Wang, Xiangjun Chen, Guannan Bai, Liangjian Ma, Xin Yang, Qiang Shu, Xuekun Li
Brain‐X.2024;[Epub] CrossRef
Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice
Vicki Wang, Kuan-Yin Tseng, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Lun Lan, Zi-Rong Chen, Kuo-Hsing Ma, Nigel H. Greig, Jin Jung, Ho-II Choi, Lars Olson, Barry J. Hoffer, Yuan-Hao Chen
Journal of Biomedical Science.2024;[Epub] CrossRef
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Rae J. Herman, Heath D. Schmidt
Physiology & Behavior.2024; 281: 114565. CrossRef
Unlocking longevity with GLP-1: A key to turn back the clock?
Vivek P. Chavda, Pankti C. Balar, Dixa A. Vaghela, Payal Dodiya
Maturitas.2024; 186: 108028. CrossRef
A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides
Kuldeep Singh, Jeetendra Kumar Gupta, Shivendra Kumar, Urvashi Soni
Current Protein & Peptide Science.2024; 25(7): 507. CrossRef
Targeting organ-specific mitochondrial dysfunction to improve biological aging
Corina T. Madreiter-Sokolowski, Ursula Hiden, Jelena Krstic, Katrin Panzitt, Martin Wagner, Christian Enzinger, Michael Khalil, Mahmoud Abdellatif, Ernst Malle, Tobias Madl, Elena Osto, Markus Schosserer, Christoph J. Binder, Andrea Olschewski
Pharmacology & Therapeutics.2024; 262: 108710. CrossRef
Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro
Maija Vaittinen, Mariana Ilha, Elena Herbers, Anita Wagner, Kirsi A. Virtanen, Kirsi H. Pietiläinen, Eija Pirinen, Jussi Pihlajamäki
Diabetes Research and Clinical Practice.2023; 199: 110635. CrossRef
The cardioprotective effect of human glucagon‐like peptide‐1 receptor agonist (semaglutide) on cisplatin‐induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways
Marwa Mohamed Atef, Yasser Mostafa Hafez, Omnia Safwat El‐Deeb, Eman H. Basha, Radwa Ismail, Hanan Alshenawy, Rasha Osama El‐Esawy, Amira Kamel Eltokhy
Cell Biochemistry and Function.2023; 41(4): 450. CrossRef
Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs
Yutong Zhou, Wendong Suo, Xinai Zhang, Jiaojiao Liang, Weizhe Zhao, Yue Wang, Hong Li, Qing Ni
Biomedicine & Pharmacotherapy.2023; 168: 115669. CrossRef
Soft X-ray tomography to map and quantify organelle interactions at the mesoscale
Valentina Loconte, Jitin Singla, Angdi Li, Jian-Hua Chen, Axel Ekman, Gerry McDermott, Andrej Sali, Mark Le Gros, Kate L. White, Carolyn A. Larabell
Structure.2022; 30(4): 510. CrossRef
Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
Belma Turan, Aysegul Durak, Yusuf Olgar, Erkan Tuncay
Molecular and Cellular Biochemistry.2022; 477(11): 2609. CrossRef
Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs
Carolin Thomas, Lia Wurzer, Ernst Malle, Michael Ristow, Corina T. Madreiter-Sokolowski
Frontiers in Aging.2022;[Epub] CrossRef
Anti-cancer effects of sitagliptin, vildagliptin, and exendin-4 on triple-negative breast cancer cells via mitochondrial modulation
POOJA JAISWAL, VERSHA TRIPATHI, ANSHUL ASSAIYA, DHARMENDRA KASHYAP, RAHUL DUBEY, ANAMIKA SINGH, JANESH KUMAR, HEM CHANDRA JHA, RAJESH SHARMA, AMIT KUMAR DIXIT, HAMENDRA SINGH PARMAR
BIOCELL.2022; 46(12): 2645. CrossRef
Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats
Ilijana Babic, Dominic Sellers, Paul L Else, Jessica Nealon, Ashleigh L Osborne, Nagesh Pai, Katrina Weston-Green
Journal of Psychopharmacology.2021; 35(3): 284. CrossRef
Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease
Vicki Wang, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Yu-Ching Chou, Zhao-Yang Fu, Li-Wen Lai, Jin Jung, Hoi-II Choi, Doo-Sup Choi, Yazhou Li, Lars Olson, Nigel H. Greig, Barry J. Hoffer, Yuan-Hao Chen
ACS Pharmacology & Translational Science.2021; 4(2): 858. CrossRef
Antioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms
Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar, Marina Sokovi
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef
Vernicia fordii (Hemsl.) Airy Shaw extract stimulates insulin secretion in pancreatic β-cells and improves insulin sensitivity in diabetic mice
Jimin Hyun, Mi Hyeon Park, Yo Han Lee, Youngeun Lee, Su Ji Jeong, Sun Sil Choi, Keon Woo Khim, Hye Jin Eom, Jin-Hoe Hur, Chan Young Park, Jae-Ick Kim, Jiyoung Park, Hyung Won Ryu, Hyun-Jun Jang, Sei-Ryang Oh, Jang Hyun Choi
Journal of Ethnopharmacology.2021; 278: 114238. CrossRef
Connecting the dots between mitochondrial dysfunction and Parkinson’s disorder: focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity
Ishnoor Kaur, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Lotfi Aleya, Simona Bungau
Environmental Science and Pollution Research.2021; 28(28): 37060. CrossRef
Neuromodulatory effects of anti-diabetes medications: A mechanistic review
Habib Yaribeygi, Milad Ashrafizadeh, Neil C. Henney, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar
Pharmacological Research.2020; 152: 104611. CrossRef
Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
Shu-Yi Wang, Shey-Lin Wu, Ta-Cheng Chen, Chieh-Sen Chuang
International Journal of Environmental Research and Public Health.2020; 17(13): 4805. CrossRef
Visualizing subcellular rearrangements in intact β cells using soft x-ray tomography
Kate L. White, Jitin Singla, Valentina Loconte, Jian-Hua Chen, Axel Ekman, Liping Sun, Xianjun Zhang, John Paul Francis, Angdi Li, Wen Lin, Kaylee Tseng, Gerry McDermott, Frank Alber, Andrej Sali, Carolyn Larabell, Raymond C. Stevens
Science Advances.2020;[Epub] CrossRef
Nutrient Sensor mTOR and OGT: Orchestrators of Organelle Homeostasis in Pancreatic β-Cells
Nicholas Esch, Seokwon Jo, Mackenzie Moore, Emilyn U. Alejandro, Yingke Xu
Journal of Diabetes Research.2020; 2020: 1. CrossRef
Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1
Ana D. Martins, Mariana P. Monteiro, Branca M. Silva, Alberto Barros, Mário Sousa, Rui A. Carvalho, Pedro F. Oliveira, Marco G. Alves
Toxicology and Applied Pharmacology.2019; 362: 1. CrossRef
Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions
Hiroshi Watanabe, Yuki Enoki, Toru Maruyama
Biological and Pharmaceutical Bulletin.2019; 42(9): 1437. CrossRef
Recent Advances in Drug Repurposing for Parkinson’s Disease
Xin Chen, Giuseppe Gumina, Kristopher G. Virga
Current Medicinal Chemistry.2019; 26(28): 5340. CrossRef
Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function
Habib Yaribeygi, Stephen L. Atkin, Amirhossein Sahebkar
Journal of Cellular Physiology.2019; 234(6): 8402. CrossRef
Liraglutide protects against glucolipotoxicity‐induced RIN‐m5F β‐cell apoptosis through restoration of PDX1 expression
Edy Kornelius, Hsin‐Hua Li, Chiung‐Huei Peng, Yi‐Sun Yang, Wei‐Jen Chen, Yan‐Zin Chang, Yi‐Chiao Bai, Stanley Liu, Chien‐Ning Huang, Chih‐Li Lin
Journal of Cellular and Molecular Medicine.2019; 23(1): 619. CrossRef
The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts
Subhashis Pal, Shailendra K. Maurya, Sourav Chattopadhyay, Shyamsundar Pal China, Konica Porwal, Chirag Kulkarni, Sabyasachi Sanyal, Rohit A. Sinha, Naibedya Chattopadhyay
Biochemical Pharmacology.2019; 164: 34. CrossRef
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
Holly Green, Panagiota Tsitsi, Ioanna Markaki, Dag Aarsland, Per Svenningsson
CNS Drugs.2019; 33(2): 143. CrossRef
Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?
Enrico Bagnoli, Una FitzGerald
European Journal of Neuroscience.2019; 49(4): 422. CrossRef
Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis
Chengcong Chen, Ying Huang, Yongmei Zeng, Xiyan Lu, Guoqing Dong
BMC Cardiovascular Disorders.2019;[Epub] CrossRef
Acute exposure to 3‑deoxyglucosone at high glucose levels impairs insulin secretion from β‑cells by downregulating the sweet taste receptor signaling pathway
Xiudao Song, Guoqiang Liang, Min Shi, Liang Zhou, Fei Wang, Lurong Zhang, Fei Huang, Guorong Jiang
Molecular Medicine Reports.2019;[Epub] CrossRef
Translational approaches to restoring mitochondrial function in Parkinson's disease
Heather Mortiboys, Ruby Macdonald, Thomas Payne, Matilde Sassani, Thomas Jenkins, Oliver Bandmann
FEBS Letters.2018; 592(5): 776. CrossRef
Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy
Eridan Rocha-Ferreira, Laura Poupon, Aura Zelco, Anna-Lena Leverin, Syam Nair, Andrea Jonsdotter, Ylva Carlsson, Claire Thornton, Henrik Hagberg, Ahad A Rahim
Brain.2018; 141(10): 2925. CrossRef
Current perspective of mitochondrial biology in Parkinson's disease
Navneet Ammal Kaidery, Bobby Thomas
Neurochemistry International.2018; 117: 91. CrossRef
Humanin promotes mitochondrial biogenesis in pancreatic MIN6 β-cells
Qingqing Qin, Jieqiong Jin, Fang He, Yongqin Zheng, Tingting Li, Yun Zhang, Jundong He
Biochemical and Biophysical Research Communications.2018; 497(1): 292. CrossRef
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson, Yazhou Li, Iciar Aviles-Olmos, Thomas T Warner, Patricia Limousin, Andrew J Lees, Nigel H Grei
The Lancet.2017; 390(10103): 1664. CrossRef
Alogliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits
Xiaowei Zhang, Zhiwei Zhang, Yungang Zhao, Ning Jiang, Jiuchun Qiu, Yajuan Yang, Jian Li, Xue Liang, Xinghua Wang, Gary Tse, Guangping Li, Tong Liu
Journal of the American Heart Association.2017;[Epub] CrossRef
Potential therapeutic interventions for chronic kidney disease‐associated sarcopenia via indoxyl sulfate‐induced mitochondrial dysfunction
Yuki Enoki, Hiroshi Watanabe, Riho Arake, Rui Fujimura, Kana Ishiodori, Tadashi Imafuku, Kento Nishida, Ryusei Sugimoto, Saori Nagao, Shigeyuki Miyamura, Yu Ishima, Motoko Tanaka, Kazutaka Matsushita, Hirotaka Komaba, Masafumi Fukagawa, Masaki Otagiri, To
Journal of Cachexia, Sarcopenia and Muscle.2017; 8(5): 735. CrossRef
The pancreas: Bandmaster of glucose homeostasis
Nathalie Jouvet, Jennifer L. Estall
Experimental Cell Research.2017; 360(1): 19. CrossRef
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
Dilan Athauda, Thomas Foltynie
Drug Discovery Today.2016; 21(5): 802. CrossRef
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus
Long Jin, Sun Woo Lim, Jian Jin, Byung Ha Chung, Chul Woo Yang
Translational Research.2016; 174: 122. CrossRef
Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases
Tae Jung, Kyung Choi
International Journal of Molecular Sciences.2016; 17(2): 192. CrossRef

Obesity and Metabolism
Mitochondrial Complexes I and II Are More Susceptible to Autophagy Deficiency in Mouse β-Cells: Min Joo Kim, Ok Kyong Choi, Kyung Sil Chae, Min Kyeong Kim, Jung Hee Kim, Masaaki Komatsu, Keiji Tanaka, Hakmo Lee, Sung Soo Chung, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Hye Seung Jung; Endocrinol Metab. 2015;30(1):65-70. Published online March 27, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.1.65

4,776 View
43 Download
4 Web of Science
3 Crossref

Abstract PDF PubReader

Background

Damaged mitochondria are removed by autophagy. Therefore, impairment of autophagy induces the accumulation of damaged mitochondria and mitochondrial dysfunction in most mammalian cells. Here, we investigated mitochondrial function and the expression of mitochondrial complexes in autophagy-related 7 (Atg7)-deficient β-cells.

Methods

To evaluate the effect of autophagy deficiency on mitochondrial function in pancreatic β-cells, we isolated islets from Atg7^F/F:RIP-Cre+ mice and wild-type littermates. Oxygen consumption rate and intracellular adenosine 5'-triphosphate (ATP) content were measured. The expression of mitochondrial complex genes in Atg7-deficient islets and in β-TC6 cells transfected with siAtg7 was measured by quantitative real-time polymerase chain reaction.

Results

Baseline oxygen consumption rate of Atg7-deficient islets was significantly lower than that of control islets (P<0.05). Intracellular ATP content of Atg7-deficient islets during glucose stimulation was also significantly lower than that of control islets (P<0.05). By Oxygraph-2k analysis, mitochondrial respiration in Atg7-deficient islets was significantly decreased overall, although state 3 respiration and responses to antimycin A were unaffected. The mRNA levels of mitochondrial complexes I, II, III, and V in Atg7-deficient islets were significantly lower than in control islets (P<0.05). Down-regulation of Atg7 in β-TC6 cells also reduced the expression of complexes I and II, with marginal significance (P<0.1).

Conclusion

Impairment of autophagy in pancreatic β-cells suppressed the expression of some mitochondrial respiratory complexes, and may contribute to mitochondrial dysfunction. Among the complexes, I and II seem to be most vulnerable to autophagy deficiency.

Citations

Citations to this article as recorded by

Proteomic pathways to metabolic disease and type 2 diabetes in the pancreatic islet
Belinda Yau, Sheyda Naghiloo, Alexis Diaz-Vegas, Austin V. Carr, Julian Van Gerwen, Elise J. Needham, Dillon Jevon, Sing-Young Chen, Kyle L. Hoehn, Amanda E. Brandon, Laurence Macia, Gregory J. Cooney, Michael R. Shortreed, Lloyd M. Smith, Mark P. Keller,
iScience.2021; 24(10): 103099. CrossRef
Natural compound oblongifolin C inhibits autophagic flux, and induces apoptosis and mitochondrial dysfunction in human cholangiocarcinoma QBC939 cells
Aiqing Zhang, Wei He, Huimin Shi, Xiaodan Huang, Guozhong Ji
Molecular Medicine Reports.2016; 14(4): 3179. CrossRef
Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells
Min Joo Kim, Ok Kyong Choi, Kyung Sil Chae, Hakmo Lee, Sung Soo Chung, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung
Islets.2015; 7(5): e1129096. CrossRef

Obesity and Metabolism
Clinical Implications of Various Criteria for the Biochemical Diagnosis of Insulinoma: Chang Ho Ahn, Lee-Kyung Kim, Jie Eun Lee, Chan-Hyeon Jung, Se-Hee Min, Kyong Soo Park, Seong Yeon Kim, Young Min Cho; Endocrinol Metab. 2014;29(4):498-504. Published online December 29, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.4.498

5,977 View
101 Download
11 Web of Science
9 Crossref

Abstract PDF PubReader

Background

Among the various diagnostic criteria for insulinoma, the ratio criteria have been controversial. However, the amended insulin-glucose ratio exhibited excellent diagnostic performance in a recent retrospective cohort study, although it has not yet been validated in other patient cohorts. We examined the diagnostic performance of the current criteria of the Endocrine Society, insulin-glucose ratio, C-peptide-glucose ratio, and amended ratios in terms of differentiating insulinomas.

Methods

We reviewed the medical records of patients who underwent evaluation for hypoglycemia from 2000 to 2013. Fourteen patients with histopathologically confirmed insulinoma and 18 patients without clinical evidence of insulinoma were included. The results of a prolonged fast test were analyzed according to the abovementioned criteria.

Results

Fulfilling all three Endocrine Society criteria-plasma levels of glucose (<3.0 mmol/L), insulin (≥8 pmol/L), and C-peptide (≥0.2 nmol/L)-exhibited 100% sensitivity and 89% specificity. Fulfilling the glucose and C-peptide criteria showed 100% sensitivity and 83% specificity, while fulfilling the glucose and insulin criteria showed 100% sensitivity and 72% specificity. Among the ratio criteria, the insulin-glucose ratio [>24.0 (pmol/L)/(mmol/L)] gave the highest area under the receiver operating characteristic curve, with 93% sensitivity and 94% specificity.

Conclusion

Fulfilling the glucose, insulin, and C-peptide criteria of the Endocrine Society guidelines exhibited the best diagnostic performance for insulinoma. Nonetheless, the insulin-glucose ratio may still have a role in the biochemical diagnosis of insulinoma.

Citations

Citations to this article as recorded by

Homeostasis Model Assessment of β-Cell Function for Diagnosis of Insulinoma
Kálmán Bódis, Martin Schön, Laura Dauben, Miriam Wilker, Klaus Strassburger, Volker Burkart, Michael Roden, Karsten Müssig
The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1125. CrossRef
Insulinoma Unmasked Post Sleeve Gastrectomy With Incidental Renal Cell Carcinoma: A Rare Case
Yashika Goel, Utkrant Kurlekar, Ashish Chitharanjan, Amruta N Beke
Cureus.2024;[Epub] CrossRef
A novel diagnostic model for insulinoma
Feng Wang, Zhe Yang, XiuBing Chen, Yiling Peng, HaiXing Jiang, ShanYu Qin
Discover Oncology.2022;[Epub] CrossRef
Comparison of the diagnostic accuracy of the current guidelines for detecting insulinoma
Laura Dauben, Marie-Christine Simon, Klaus Strassburger, Volker Burkart, Katharina S Weber, Sven Schinner, Michael Roden, Karsten Müssig
European Journal of Endocrinology.2019; 180(6): 381. CrossRef
EUS-guided lauromacrogol ablation of insulinomas: a novel treatment
Shanyu Qin, Yongru Liu, Hongjian Ning, Lin Tao, Wei Luo, Donghong Lu, Zuojie Luo, Yingfen Qin, Jia Zhou, Junqiang Chen, Haixing Jiang
Scandinavian Journal of Gastroenterology.2018; 53(5): 616. CrossRef
Diagnosis of insulinoma using the ratios of serum concentrations of insulin and C-peptide to glucose during a 5-hour oral glucose tolerance test
Xu Li, Feng Zhang, Haibing Chen, Haoyong Yu, Jian Zhou, Ming Li, Qing Li, Lianxi Li, Jun Yin, Fang Liu, Yuqian Bao, Junfeng Han, Weiping Jia
Endocrine Journal.2017; 64(1): 49. CrossRef
Insulinoma in a 5‐Year‐Old Dexter Cow
C. Binici, S. Plog, O. Kershaw, M. Schmicke, J.H. van der Kolk, K.E. Müller
Journal of Veterinary Internal Medicine.2016; 30(4): 1402. CrossRef
Vague neuroglycopenic complaints camouflage diagnosis of adolescent insulinoma: a case report
Kelsee Halpin, Ryan McDonough, Patria Alba, Jared Halpin, Vivekanand Singh, Yun Yan
International Journal of Pediatric Endocrinology.2016;[Epub] CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef

Obesity and Metabolism
Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: Young Min Cho, Rhonda D. Wideman, Timothy J. Kieffer; Endocrinol Metab. 2013;28(4):262-274. Published online December 12, 2013; DOI: https://doi.org/10.3803/EnM.2013.28.4.262

6,567 View
88 Download
38 Crossref

Abstract PDF PubReader

Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which contributes to decreased postprandial glycemic excursions. In the 1990s, chronic subcutaneous infusion of GLP-1 was found to lower blood glucose levels in patients with type 2 diabetes. However, GLP-1's very short half-life, arising from cleavage by the enzyme dipeptidyl peptidase 4 (DPP-4) and glomerular filtration by the kidneys, presented challenges for clinical use. Hence, DPP-4 inhibitors were developed, as well as several GLP-1 analogs engineered to circumvent DPP-4-mediated breakdown and/or rapid renal elimination. Three categories of GLP-1 analogs, are being developed and/or are in clinical use: short-acting, long-acting, and prolonged-acting GLP-1 analogs. Each class has different plasma half-lives, molecular size, and homology to native GLP-1, and consequently different characteristic effects on glucose metabolism. In this article, we review current clinical data derived from each class of GLP-1 analogs, and consider the clinical effects reported for each category in recent head to head comparison studies. Given the relatively brief clinical history of these compounds, we also highlight several important efficacy and safety issues which will require further investigation.

Citations

Citations to this article as recorded by

Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide
Jin Kyung Park, Zhengyu Piao, Hyun Jung Lee, Byeongmoon Jeong
Biomacromolecules.2024; 25(8): 4946. CrossRef
The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
Jhih-Syuan Liu, Sheng-Chiang Su, Feng-Chih Kuo, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Kuan-Chan Chen, Yi-Chen Liu, Chih-Ping Lin, An-Che Cheng, Chien-Hsing Lee, Fu-Huang Lin, Yi-Jen Hung, Hsin-Ya Liu, Chieh-Hua Lu, Chang-Hsun Hsieh
Medicine.2023; 102(10): e33167. CrossRef
Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
Mariya Kalinkova, Tanya Kadiyska, Teodora Handjieva-Darlenska
Pharmacia.2023; 70(2): 383. CrossRef
Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation
Irem Mert, Ayhan Cetinkaya, Mujgan Gurler, Canan Akünal Turel, Humeyra Celik, Ibrahim Ethem Torun, Idris Turel
Inflammopharmacology.2022; 30(3): 1093. CrossRef
Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
Chuanmin Bai, Yujun Wang, Zhi Niu, Yaxin Guan, Jingshan Huang, Xin Nian, Fan Zuo, Juan Zhao, Tsutomu Kazumi, Bin Wu
Frontiers in Endocrinology.2022;[Epub] CrossRef
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Hun Jee Choe, Young Min Cho
Endocrinology and Metabolism.2021; 36(1): 22. CrossRef
Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice
Xingchun Wang, Bingwei Ma, Jiaqi Chen, Hui You, Chunjun Sheng, Peng Yang, Shen Qu, Vito Angelo Giagulli
International Journal of Endocrinology.2021; 2021: 1. CrossRef
Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin
Zeinab A. Saad, Dina M. Khodeer, Sawsan A. Zaitone, Amal A.M. Ahmed, Yasser M. Moustafa
Life Sciences.2020; 253: 117725. CrossRef
Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
Shan Li, Xiaoman Wang, Jielei Zhang, Jingyi Li, Xiaogang Liu, Yuanyuan Ma, Chao Han, Lixia Zhang, Lili Zheng
Brazilian Journal of Medical and Biological Research.2018;[Epub] CrossRef
Efficacy and safety of combination therapy with an α‐glucosidase inhibitor and a dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta‐analysis
Se Hee Min, Jeong‐Hwa Yoon, Seokyung Hahn, Young Min Cho
Journal of Diabetes Investigation.2018; 9(4): 893. CrossRef
Glucagon-like peptide-1 affects human umbilical vein endothelial cells in high glucose by the PI3K/Akt/eNOS signaling pathway
Jie Wu, Pingfan Guo, Tianmin He, Fanggang Cai
Turkish Journal of Biochemistry.2018; 43(2): 119. CrossRef
What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus
Wing B. Chan, Andrea Luk, Wing S. Chow, Vincent T.F. Yeung
Journal of Diabetes.2017; 9(6): 562. CrossRef
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
L. Østergaard, Christian S. Frandsen, S. Madsbad
Expert Review of Clinical Pharmacology.2016; 9(2): 241. CrossRef
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Johan Jendle, George Grunberger, Thomas Blevins, Francesco Giorgino, Ryan T. Hietpas, Fady T. Botros
Diabetes/Metabolism Research and Reviews.2016; 32(8): 776. CrossRef
Glucagon‐like peptide‐1(GLP‐1) receptor agonists: potential to reduce fracture risk in diabetic patients?
Guojing Luo, Hong Liu, Hongyun Lu
British Journal of Clinical Pharmacology.2016; 81(1): 78. CrossRef
Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?
Sten Madsbad
Journal of Diabetes and its Complications.2016; 30(2): 374. CrossRef
Risk assessment and management of post-transplant diabetes mellitus
Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
Metabolism.2016; 65(10): 1559. CrossRef
Recent advances in oral delivery of peptide hormones
Pegah Varamini, Istvan Toth
Expert Opinion on Drug Delivery.2016; 13(4): 507. CrossRef
Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
PLOS ONE.2016; 11(12): e0166913. CrossRef
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Sten Madsbad
Diabetes, Obesity and Metabolism.2016; 18(4): 317. CrossRef
Does Bosentan Protect Diabetic Brain Alterations in Rats? The Role of Endothelin‐1 in the Diabetic Brain
Recep Demir, Elif Cadirci, Erol Akpinar, Yasemin Cayir, Hasan Tarik Atmaca, Harun Un, Celalettin Semih Kunak, Muhammed Yayla, Zafer Bayraktutan, Ilknur Demir
Basic & Clinical Pharmacology & Toxicology.2015; 116(3): 236. CrossRef
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
P. D. Home, P. Shamanna, M. Stewart, F. Yang, M. Miller, C. Perry, M. C. Carr
Diabetes, Obesity and Metabolism.2015; 17(2): 179. CrossRef
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Jaime A. Davidson
Postgraduate Medicine.2015; 127(8): 827. CrossRef
GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
Jia Liu, Guang Wang, Yumei Jia, Yuan Xu
Diabetes/Metabolism Research and Reviews.2015; 31(4): 329. CrossRef
Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial
M. K. Kim, E.‐J. Rhee, K. A. Han, A. C. Woo, M.‐K. Lee, B. J. Ku, C. H. Chung, K.‐A. Kim, H. W. Lee, I. B. Park, J. Y. Park, H. C. Chul Jang, K. S. Park, W. I. Jang, B. Y. Cha
Diabetes, Obesity and Metabolism.2015; 17(3): 309. CrossRef
Incretin physiology and pathophysiology from an Asian perspective
Young Min Cho
Journal of Diabetes Investigation.2015; 6(5): 495. CrossRef
Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J2015;39:74-81)
Antoni Sicras-Mainar, Ruth Navarro-Artieda
Diabetes & Metabolism Journal.2015; 39(2): 173. CrossRef
Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
Se Hee Min, Young Min Cho
The Journal of Korean Diabetes.2015; 16(4): 252. CrossRef
Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells
Min Joo Kim, Ok Kyong Choi, Kyung Sil Chae, Hakmo Lee, Sung Soo Chung, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung
Islets.2015; 7(5): e1129096. CrossRef
Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
Mi Yeon Kang, Tae Jung Oh, Young Min Cho
Endocrinology and Metabolism.2015; 30(2): 216. CrossRef
Interleukin-6 CpG Methylation and Body Weight Correlate Differently in Type 2 Diabetes Patients Compared to Obese and Lean Controls
Eva Aumueller, Marlene Remely, Hanna Baeck, Berit Hippe, Helmut Brath, Alexander G. Haslberger
Lifestyle Genomics.2015; 8(1): 26. CrossRef
The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells
Hirohisa Onuma, Kouichi Inukai, Atsuko Kitahara, Rie Moriya, Susumu Nishida, Toshiaki Tanaka, Hidenori Katsuta, Kazuto Takahashi, Yoshikazu Sumitani, Toshio Hosaka, Hitoshi Ishida
Biochemical and Biophysical Research Communications.2014; 451(2): 339. CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef
Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone
Dorit Naot, Jillian Cornish
Frontiers in Endocrinology.2014;[Epub] CrossRef
Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
Maria Voukali, Irene Kastrinelli, Sapfo Stragalinou, Dimitra Tasiopoulou, Pinelopi Paraskevopoulou, Nicholas Katsilambros, Alexandros Kokkinos, Nicholas Tentolouris, Ioannis Ioannidis
Journal of Diabetes Research.2014; 2014: 1. CrossRef
The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?
Mark F McCarty, James J DiNicolantonio
Open Heart.2014; 1(1): e000103. CrossRef
Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad
J.J. Gorgojo-Martínez
Hipertensión y Riesgo Vascular.2014; 31(2): 45. CrossRef
Managing Loss of Glycemic Control in Middle-Aged Patients With Diabetes: The Role of GLP-1 Receptor Agonists in Combination-Therapy Regimens
Thomas B. Repas
Journal of Osteopathic Medicine.2014; 114(s52): 14. CrossRef

Obesity and Metabolism
A Novel Mutation in the Von Hippel-Lindau Tumor Suppressor Gene Identified in a Patient Presenting with Gestational Diabetes Mellitus: Yun Hyi Ku, Chang Ho Ahn, Chan-Hyeon Jung, Jie Eun Lee, Lee-Kyung Kim, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho; Endocrinol Metab. 2013;28(4):320-325. Published online December 12, 2013; DOI: https://doi.org/10.3803/EnM.2013.28.4.320

4,186 View
29 Download
4 Crossref

Abstract PDF PubReader

Background

Von Hippel-Lindau (VHL) disease is an autosomal dominantly inherited, multisystemic tumor syndrome caused by mutations in the VHL gene. To date, more than 1,000 germline and somatic mutations of the VHL gene have been reported. We present a novel mutation in the VHL tumor suppressor gene that presented with gestational diabetes mellitus.

Methods

A 30-year-old woman presented with gestational diabetes mellitus. She sequentially showed multiple pancreatic cysts, spinal cord hemangioblastoma, cerebellar hemangioblastoma, and clear cell type renal cell carcinomas. Also, her father and brother had brain hemangioblastomas. Each of the three exons of the VHL gene was individually amplified by polymerase chain reaction and direct sequencing was performed using an ABI 3730 DNA analyzer.

Results

DNA sequence analysis to determine the presence of VHL mutation in her family revealed del291C, a novel frameshift mutation.

Conclusion

We found a novel mutation in the VHL tumor suppressor gene that presented with gestational diabetes mellitus.

Citations

Citations to this article as recorded by

Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review
Yanlei Wang, Zhaoxiang Liu, Wenhui Zhao, Chenxiang Cao, Luqi Xiao, Jianzhong Xiao
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1611. CrossRef
Retinal hemangioblastoma in a patient with Von Hippel-Lindau disease: A case report and literature review
Yikeng Huang, Weiwen Hu, Xionggao Huang
Frontiers in Oncology.2022;[Epub] CrossRef
Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms
Claudia von Arx, Monica Capozzi, Elena López-Jiménez, Alessandro Ottaiano, Fabiana Tatangelo, Annabella Di Mauro, Guglielmo Nasti, Maria Lina Tornesello, Salvatore Tafuto
Journal of Clinical Medicine.2019; 8(9): 1277. CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef

Thyroid
Two Cases of Methimazole-Induced Insulin Autoimmune Syndrome in Graves' Disease: Eun Roh, Ye An Kim, Eu Jeong Ku, Jae Hyun Bae, Hye Mi Kim, Young Min Cho, Young Joo Park, Kyong Soo Park, Seong Yeon Kim, Soo Heon Kwak; Endocrinol Metab. 2013;28(1):55-60. Published online March 25, 2013; DOI: https://doi.org/10.3803/EnM.2013.28.1.55

7,372 View
77 Download
18 Crossref

Abstract PDF PubReader

We report here the cases of two females with Graves' disease who developed insulin autoimmune syndrome after treatment with methimazole. The patients exhibited a sudden altered mental state after treatment with methimazole for approximately 4 weeks. Patients had hypoglycemia with serum glucose below 70 mg/dL, and laboratory findings showed both high levels of serum insulin and high titers of insulin autoantibodies. The two women had never been exposed to insulin or oral antidiabetic agents, and there was no evidence of insulinoma in imaging studies. After glucose loading, serum glucose, and total insulin levels increased abnormally. One of the patient was found to have HLA-DRB1*0406, which is known to be strongly associated with methimazole-induced insulin autoimmune syndrome. After discontinuation of methimazole, hypoglycemic events disappeared within 1 month. Insulin autoantibody titer and insulin levels decreased within 5 months and there was no further development of hypoglycemic events. We present these cases with a review of the relevant literature.

Citations

Citations to this article as recorded by

A Case of Methimazole-Induced Insulin Autoimmune Syndrome and Literature Review
东昕王
Advances in Clinical Medicine.2024; 14(10): 19. CrossRef
HLA Alleles Associate with Insulin Autoimmune Syndrome
Dan Yao, Jiefeng Jiang, Qianyun Zhou, Caiyun Feng, Jianping Chu, Zhiyan Chen, Jie Yang, Jinying Xia, Yujia Chen
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 3463. CrossRef
Methimazole-Induced Insulin Autoimmune Syndrome in a Korean Patient with Graves’ Disease Treated with Propylthiouracil: a Case Report and Literature Review
Sun Hee Kim, Cho-ok Baek, Sun Kyung Song, Ji Hye Kim
International Journal of Thyroidology.2024; 17(2): 295. CrossRef
Insulin Autoimmune Syndrome: A Systematic Review
MingXu Lin, YuHua Chen, Jie Ning, Tatsuya Kin
International Journal of Endocrinology.2023; 2023: 1. CrossRef
Safety of Antithyroid Drugs in Avoiding Hyperglycemia or Hypoglycemia in Patients With Graves’ Disease and Type 2 Diabetes Mellitus: A Literature Review
Yu-Shan Hsieh
Cureus.2023;[Epub] CrossRef
Case report: hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in young Taiwanese woman with Graves’ disease
Hsuan-Yu Wu, I-Hua Chen, Mei-Yueh Lee
Medicine.2022; 101(25): e29337. CrossRef
Analysis of the clinical characteristics of insulin autoimmune syndrome induced by methimazole
Linli Sun, Weijin Fang, Dan Yi, Wei Sun, Chunjiang Wang
Journal of Clinical Pharmacy and Therapeutics.2021; 46(2): 470. CrossRef
Preoperative plasmapheresis experience in Graves’ disease patients with anti-thyroid drug-induced hepatotoxicity
Tugce Apaydın, Onur Elbasan, Dilek Gogas Yavuz
Transfusion and Apheresis Science.2020; 59(5): 102826. CrossRef
Glycemic variation in uncontrolled Graves’ disease patients with normal glucose metabolism: Assessment by continuous glucose monitoring
Gu Gao, Feng-fei Li, Yun Hu, Reng-na Yan, Bing-li Liu, Xiao-mei Liu, Xiao-fei Su, Jian-hua Ma, Gang Hu
Endocrine.2019; 64(2): 265. CrossRef
Insulin autoimmune syndrome induced by exogenous insulin injection: a four-case series
Yimin Shen, Xiaoxiao Song, Yuezhong Ren
BMC Endocrine Disorders.2019;[Epub] CrossRef
Assessment and Management of Anti-Insulin Autoantibodies in Varying Presentations of Insulin Autoimmune Syndrome
David Church, Luís Cardoso, Richard G Kay, Claire L Williams, Bernard Freudenthal, Catriona Clarke, Julie Harris, Myuri Moorthy, Efthmia Karra, Fiona M Gribble, Frank Reimann, Keith Burling, Alistair J K Williams, Alia Munir, T Hugh Jones, Dagmar Führer,
The Journal of Clinical Endocrinology & Metabolism.2018; 103(10): 3845. CrossRef
MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemia
Nana Esi Kittah, Adrian Vella
European Journal of Endocrinology.2017; 177(1): R37. CrossRef
Insulin autoimmune syndrome during the administration of clopidogrel
Eijiro Yamada, Shuichi Okada, Tsugumichi Saito, Aya Osaki, Atushi Ozawa, Masanobu Yamada
Journal of Diabetes.2016; 8(4): 588. CrossRef
Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog
Chih-Ting Su, Yi-Chun Lin
Endocrinology, Diabetes & Metabolism Case Reports.2016;[Epub] CrossRef
Anti-tuberculosis Treatment-Induced Insulin Autoimmune Syndrome
Jung Suk Han, Han Ju Moon, Jin Seo Kim, Hong Il Kim, Cheol Hyeon Kim, Min Joo Kim
The Ewha Medical Journal.2016; 39(4): 122. CrossRef
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
Douglas S. Ross, Henry B. Burch, David S. Cooper, M. Carol Greenlee, Peter Laurberg, Ana Luiza Maia, Scott A. Rivkees, Mary Samuels, Julie Ann Sosa, Marius N. Stan, Martin A. Walter
Thyroid.2016; 26(10): 1343. CrossRef
Insulin Autoimmune Syndrome in a Patient with Hashimoto's Thyroiditis
In Wook Song, Eugene Han, Nan Hee Cho, Ho Chan Cho
Journal of Korean Thyroid Association.2014; 7(2): 180. CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef

A Case of Aortic Dissection Associated with Cushing's Syndrome.: Soo Heon Kwak, Eun Jung Lee, Sun Wook Cho, Hyung Jin Choi, Eun Kyung Lee, Young Min Cho, Seong Yeon Kim; J Korean Endocr Soc. 2006;21(6):556-559. Published online December 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.6.556

1,949 View
27 Download

Abstract PDF: Herein is reported the case of a 43-year-old woman, who experienced an acute aortic dissection associated with underlying Cushing's syndrome. The patient had central obesity and a moon face of ten years duration, but had never sought medical consultation. On the day of her presentation, she experienced a severe chest pain radiating to her back. Computed tomography revealed a Stanford type B acute aortic dissection and a left adrenal mass. From her hormonal study results, clinical symptoms and signs, she was diagnosed with Cushing's syndrome, which was due to a left adrenal adenoma. After medical treatment to stabilize the aortic dissection, she underwent left adrenalectomy. The aortic lesion of the present patient suggests that hypercortisolemia arising from Cushing's syndrome might be related to the development of acute aortic dissection.

Cystic Insulinoma of the Pancreas.: Sun Wook Cho, Eun Jung Lee, Soo Heon Kwak, Young Min Cho, Chan Soo Shin, Kyong Soo Park, Seong Yeon Kim, Bo Youn Cho, Hong Kyu Lee; J Korean Endocr Soc. 2006;21(6):552-555. Published online December 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.6.552

1,972 View
39 Download

Abstract PDF: Cystic islet cell neoplasms are among the rarest entities in the differential diagnosis of cystic tumor of the pancreas, and this malady raises difficult clinical problems. The diagnosis of insulinoma could be difficult if the functional activity is incomplete, which possibly leads to blunted symptoms of hypoglycemia and failure in the laboratory to provide evidence of hyperinsulinemia. Furthermore, if the imaging shows a smaller tumor than usual or an unusual morphology like cyctic tumor, then physicians can become somewhat confused. We report here on a clinical case of cystic insulinoma with the typical neuroglycopenic symptoms and laboratory-confirmed hyperinsulinemia. At resection, a 2-cm cavitary mass without central necrosis was excised and this was confirmed histologically as a purely cystic insulioma. This is the first report of a functional cystic insulinoma of the pancreas in Korea. We suggest that the differential diagnosis of endocrine tumor must be considered for any pancreatic cyst, and especially when it is discovered in a patient who is clinically suggestive of having the associated syndrome.

A Case of Adrenocortical Carcinoma showing Variable Cortisol Production during the Clinical Course.: Yun Hyi Ku, Hyung Jin Choi, Jin Taek Kim, Ji Won Yoon, Eun Kyung Lee, Hwa Young Cho, Mi Yeon Kang, Jie Seon Lee, Young Min Cho, Seong Yeon Kim; J Korean Endocr Soc. 2006;21(5):419-423. Published online October 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.5.419

1,703 View
21 Download

Abstract PDF: Patients with adrenocortical carcinoma (ACC) present with evidence of excessive adrenal steroid hormone in approximately 60% of cases, in which rapidly progressing Cushing's syndrome with or without virilization is the most frequent presentation. Some patients experience an increase or a decline in cortisol production through the progression of their ACC. We report on an unusual case of a cortisol-producing ACC, and the patient presented with a decline in cortisol production, followed by an increase in cortisol production, through the progression of the tumor. A 65-year-old woman who manifested with facial edema and weight gain was diagnosed with Cushing's syndrome, caused by cortisol producing ACC. The patient was treated with adrenalectomy. However, 8 months later, a metastatic hepatic tumor of recurred ACC was detected. At that time, the hormonal evaluation revealed that the liver mass did not produce any hormones. The patient was treated with metastatectomy. Four months later, a relapsed tumor was detected. Increased cortisol production was observed at that time. We speculate there was a change in the clonal dominance within the ACC and this change might cause such a difference. This is the first case report of ACC that showed variable hormone production during progression.

A case of Paraganglioma Arising in the Transverse Mesocolon.: Hong Il Kim, Bo kyung Koo, You Jin Lee, Jin Taek Kim, Young Min Cho, Kuhn Uk Lee, Seong Yeon Kim; J Korean Endocr Soc. 2005;20(5):496-501. Published online October 1, 2005; DOI: https://doi.org/10.3803/jkes.2005.20.5.496

1,958 View
17 Download
1 Crossref

Abstract PDF

Herein, a case of a solitary primary paraganglioma arising in the mesentery, found in a hypertensive 70-year-old woman, who presented with nausea and postprandial abdominal discomfort, is reported. Ultrasonography and computed tomography showed a hypervascular mass abutting the second portion of the duodenum. An exploratory laparotomy revealed a 5.5 x 5.3 x 5cm sized mass in the mesentery of the transverse colon, which was histologically proven to be a paraganglioma. No intraoperative hemodynamic changes developed, and the postoperative course was uneventful. To our knowledge, this is the first case of a paraganglioma arising in the mesentery reported in Korea. Considering the unusual locations and the associated operative risk, it is necessary to rule out the possibility of a functioning paraganglioma in the preoperative differential diagnosis of an abdominal mass.

Citations

Citations to this article as recorded by

Mesenteric Lesions with Similar or Distinctive Appearances on CT
Hwajin Cha, Jiyoung Hwang, Seong Sook Hong, Eun Ji Lee, Hyun-joo Kim, Yun-Woo Chang
Journal of the Korean Society of Radiology.2019; 80(6): 1091. CrossRef

A Case of Primary Reninism Manifested by Hypertension with Hypokalemia.: Hyung Jin Choi, Eui Sil Hong, Young Min Cho, Do Joon Park, Chan Soo Shin, Kyong Soo Park, Seong Yeon Kim, Bo Youn Cho, Hong Kyu Lee; J Korean Endocr Soc. 2005;20(2):168-173. Published online April 1, 2005; DOI: https://doi.org/10.3803/jkes.2005.20.2.168

2,184 View
31 Download
1 Crossref

Abstract PDF

Primary reninism is a rare cause of hypertension manifesting along with hypokalemia. A high level of plasma renin activity and a high level of serum aldosterone are the whole markers of primary reninism. Upon making the diagnosis of primary reninism, other more common causes of aldosteronism must be differentiated, such as renovascular hypertension and primary aldosteronism. Primary reninism is commonly caused by juxtaglomerular cell tumor, which is one of the curable causes of hypertension, and this can be successfully treated by conservative surgery. We report here on a case of primary reninism that was caused by juxtaglomerular cell tumor that developed in a 22-year-old female patient. She was recently diagnosed with hypertension and hypokalemia. She had markedly elevated plasma renin activity and an increased serum aldosterone concentration. Computed tomography revealed a mass located in the right kidney and selective renal vein sampling suggested that the mass was secreting an excess of renin. Right nephrectomy was done and her hypertension with hypokalemia was successfully treated. We report here a case of primary reninism that presented with juxtaglomerular cell tumor along with a review of the literature

Citations

Citations to this article as recorded by

Reninoma: a rare cause of curable hypertension
Ji Hye Kim, Ji Hyun Kim, Myung Hyun Cho, Eujin Park, Hye Sun Hyun, Yo Han Ahn, Hee Gyung Kang, Kyung Chul Moon, Il-Soo Ha, Hae Il Cheong
Korean Journal of Pediatrics.2019; 62(4): 144. CrossRef

A Case of Protein-losing Enteropathy with an Abnormal Cortisol Response to ACTH Stimulation.: Hong Il Kim, Bo Kyeong Koo, You Jin Lee, Eun Jung Lee, Soo Heon Kwak, Sun Wook Cho, Hyung Jin Choi, Young Min Cho, Seong Yeon Kim; J Korean Endocr Soc. 2005;20(1):90-95. Published online February 1, 2005; DOI: https://doi.org/10.3803/jkes.2005.20.1.90

1,903 View
31 Download

Abstract PDF: We hereby report a case of a 62-year-old male patient who was misdiagnosed with adrenal insufficiency during the course of protein-losing enteropathy caused by superior mesenteric arterial thrombosis. The patient was suspected to have adrenal insufficiency due to hyponatremia and severe weakness. The cortisol responses to the initial challenge of 250microgram ACTH were inadequate (maximum serum cortisol level after ACTH challenge was 10.9microgram/dL), while the serum albumin concentration was 1.9g/dL. Subsequently, intravenous steroid therapy was given to the patient. However, after bowel resection, the serum albumin level increased to 3.4g/dL and the cortisol response to the follow-up rapid ACTH stimulation was completely normal. Accordingly, we discontinued steroid replacement and discharged the patient without any problem. In conclusion, measuring total serum cortisol in a patient with hypo-pro-teinemia may lead to misdiagnosis of adrenal insufficiency. In such cases, caution should be exercised in interpreting the results in terms of total serum cortisol level or measurement of serum free cortisol levels should be considered.

The Efficacy of MIBG Scan as a Diagnostic and Docalization Test for Pheochromocytoma.: Cheol Ku Park, Kyeong Won Kim, Do Hee Kim, Jae Hyeon Kim, Jun Gu Kang, San Wan Kim, Young Min Cho, Do Joon Park, Chan Soo Shin, Kyong Soo Park, Bo Youn Cho, Hong Kyu Lee, Seong Yeon Kim; J Korean Endocr Soc. 2005;20(1):21-28. Published online February 1, 2005; DOI: https://doi.org/10.3803/jkes.2005.20.1.21

1,828 View
20 Download

Abstract PDF: BACKGROUND
Computed tomography(CT) is currently considered as the initial imaging procedure of choice for the localization of pheochromocytomas in most of the cases. 131I-or 123I-Metaiodobenzylguanidine scintigraphy(MIBG scan) was proven to be a highly specific tool for the detection of adrenal and extra-adrenal pheochromocytomas, but was less sensitive than CT. The present study is aimed to evaluate the usefulness of a MIBG scan in diagnosis and localization of pheochromocytoma when compared to CT. METHODS: We retrospectively evaluated 27 patients who underwent a MIBG scan for a pheochromocytoma at the Seoul National University Hospital from the year 2000 and 2002. According to the pathological and clinical findings, in 16 the patients pheochromocytoma was confirmed to be positive and the rest 11 of the patients were excluded from the study. RESULTS: Pheochromocytomas was identified in 16 patients. Eleven of them were localized in adrenal gland and 5 were extra-adrenal lesions. The sensitivity to MIBG scan in adrenal lesions and extra-adrenal lesions, was 72%(8/11) and 40%(2/5) respectively. In our study, the overall sensitivity to MIBG scan was 62%(10/16), and overall specificity was 90.9%(10/11). By CT four were identified to have equivocal biochemical abnormalities, but were definite and extraadrenal tumors by MIBG scan showed abnormal uptakes in two of them. CONCLUSION: The MIBG scan was especially useful in 2 of the 27 patients but we had no experienced about the additional benefits of a MIBG scan in the other 25 cases. Our results reveal that a MIBG scan should be performed carefully for the diagnosis and localization of a pheochromocytoma, while considering cost and time of operation.

Diagnostic Value of 1microgram Rapid ACTH Stimulation Test According to the Timing of Sampling of Serum Cortisol in Patients with Suspected Central Adrenal Insufficiency.: Sang Wan Kim, Young Min Cho, Do Joon Park, Chan Soo Shin, Kyung Soo Park, Seong Yeon Kim, Bo Youn Cho, Hong Kyu Lee; J Korean Endocr Soc. 2004;19(1):33-41. Published online February 1, 2004

1,396 View
20 Download

Abstract PDF: BACKGROUND
Traditional testing of the hypothalamic-pituitary-adrenal axis function has essentially relied upon the insulin tolerance test or the metyrapone test(both tests are not only uncomfortable, but are also dangerous). The standard ACTH stimulation test uses an extremely supra-physiologic amount(250f microgram) of ACTH to evaluate a physiological response, which may result in a false normal response. The 1microgram rapid ACTH stimulation test is more physiological and more sensitive than the standard test, but there exist much controversy about when the serum cortisol should be measured or what the most appropriate cut-off point is for normality or whether the 1microgram ACTH commercial solution is needed. The aims of this study were to investigate 1) whether 1microgram of ACTH is an appropriate amount to stimulate the adrenal gland of patients that have suspected central adrenal insufficiency compared with insulin tolerance test(ITT) and 2) the diagnostic value of the 1microgram rapid ACTH stimulation test according to timing of sampling of serum cortisol. METHODS: In order to evaluate the dose-response relationship between ACTH and cortisol, we performed the ITT in 77 patients with suspected central adrenal insufficiency with serial measurements of serum cortisol and plasma ACTH. We drew the blood samples in 10 min intervals between 10 and 60 min after the administration of 1microgram ACTH in 39 patients with central adrenal insufficiency and in 38 pituitary control patients with pituitary. ITT was used to confirm the diseases for the patients of central adrenal insufficiency, but for pituitary control patients, the ITT indicated normality in the patients. Also, all subjects underwent the 250microgram rapid ACTH stimulation test, and we compared the diagnostic value of the 1microgram ACTH stimulation test with the 250microgram test. RESULTS: 1) The plasma ACTH level after the 1microgram ACTH stimulation test, even if it was be assumed as approximately 300pg/mL, was expected to be sufficient enough to stimulate the adrenal cortex normally(serum cortisol levels >18microgram/dL) compared to the plasma ACTH level in the ITT. 2) The sensitivity and specificity of the 1microgram rapid ACTH stimulation test was highest with 92.3% and 84.2%, respectively, when serum cortisol levels were measured at 20, 30, and 40 min after the ACTH injection. The 1microgram rapid ACTH stimulation test was more sensitive than the 250microgram ACTH test(sensitivity: 92.3%, specificity: 71.8%). CONCLUSION: The 1microgram rapid ACTH stimulation test was more sensitive test in patients with suspected central adrenal insufficiency, and blood samples for cortisol levels should be drawn at 20, 30, and 40 min after ACTH administration.

Interaction of Pituitary Adenylate Cyclase-Activating Polypeptide and Angiotensin II on Aldosterone Production in Human Adrenocortical H295R Cells.: Seong Yeon Kim, Sang Wan Kim, Young Min Cho, Do Joon Park, Chan Soo Shin, Kyung Soo Park, Bo Youn Cho, Hong Kye Lee; J Korean Endocr Soc. 2003;18(3):272-282. Published online June 1, 2003

1,102 View
19 Download

Abstract PDF: BACKGROUND
Evidence is accumulating that aldosterone secretion can be regulated in a paracrine and/or an autocrine manner by several neuropeptides locally released within the adrenal gland. Among neuropeptides, pituitary adenylate cyclase-activating polypeptide (PACAP) is present in high concentration in the human adrenal gland. The purpose of this study was to investigate the action of PACAP and the interaction between PACAP and angiotensin II (AII), the main physiologic aldosterone secretagogue, in aldosterone production in human H295R adrenocortical cells. METHODS: H295R cells were incubated with increasing concentrations of PACAP (10(-11)M~10(-7)M) in the absence or presence of 10(-7)M AII. Aldosterone concentration in the supernatant was determined by RIA. Intracellular cAMP content was measured by RIA and total inositol phosphate (IP) production by anion exchange chromatography. Gene expression of CYP11B2 was studied by RT-PCR. RESULTS: In H295R cells, PACAP stimulated aldosterone production in a dose-dependent manner. Incubation of H295R cells with PACAP in the presence of AII significantly increased aldosterone production, compared with that of PACAP alone. PACAP dose-dependently increased cAMP production, but 10(-7)M AII had no effect on either basal or PACAP-stimulated cAMP production. Total IP production was not affected by PACAP, but was increased by 10(-7)M AII; an increase that was not further increased by addition of PACAP. RT-PCR analysis of H295R cells which were exposed to 10-7M PACAP or 10(-7)M AII showed an increase in CYP11B2 transcript signal. Induction of CYP11B2 mRNA expression in response to treatment with both PACAP and AII was significantly more than that resulting from using PACAP alone. CONCLUSION: The present study demonstrates that PACAP exerts a direct stimulatory effect on aldosterone production through induction of CYP11B2 mRNA expression by adenylate cyclase activation as the main intracellular signal pathway in H295R cells. Furthermore, there may be some additive effects between PACAP and AII on aldosterone production.

Metabolic Syndrome.: Min Kyong Moon, Young Min Cho, Soo Lim, Kyong Soo Park, Hong Kyu Lee; J Korean Endocr Soc. 2003;18(2):105-119. Published online April 1, 2003

994 View
19 Download

Abstract PDF: No abstract available.

A Case of Acute Suppurative Thyroiditis as a Complication of Acupuncture in Patient with a Benign Thyroid Nodule.: Tae Yong Kim, Han Mo Yang, Jae Kyung Hwang, Young Min Cho, Young Joo Park, Do Joon Park, Seong Yeon Kim, Hong Kyu Lee, Bo Youn Cho; J Korean Endocr Soc. 2002;17(4):576-582. Published online August 1, 2002

1,401 View
25 Download

Abstract PDF: Acute suppurative thyroiditis is an uncommon disease, and usually affects patients with preexisting thyroid gland pathology. Penetrating injury could provide an acquired channel for the infection to spread into the relatively infection-resistant thyroid gland. We describe the first case of acute suppurative thyroiditis, as a complication of acupuncture, in a patient with a benign thyroid nodule. A 54-year-old male received acupuncture on his neck for the treatment of a previously diagnosed thyroid nodule. Four days after the acupuncture, the patient was admitted due to severe pain of the anterior neck and odynophagia. Fever and tenderness over the thyroid gland were observed. Burkholderia cepacia was isolated from a culture dish of aspirate of the thyroid gland. A neck computed tomography scan showed an abscess in the thyroid gland. Antibiotic treatment, and repeated drainage of the abscess, ameliorated the symptoms of infection. Two weeks after admission, the patient was discharged without sequela. Acupuncture should be considered as a kind of penetrating injury, which may induce acute suppurative thyroiditis.

Changes in Plasma Leptin Levels Relating to Short-Term Thyroid Manipulation in Rats.: Min Seon Kim, Cho Ya Yoon, Young Min Cho, Hye Seung Jung, Chan Soo Shin, Kyong Soo Park, Seong Yeon Kim, Bo Youn Cho, Hong Kyu Lee, Stephen R Bloom; J Korean Endocr Soc. 2002;17(2):197-205. Published online April 1, 2002

1,240 View
21 Download

Abstract PDF: BACKGROUND
Leptin, an adipocyte derived hormone, and thyroid hormone have similar effects on energy homeostasis, such that a shortage of both hormones is associated with decreased energy expenditure and increased body weight. Therefore, for the maintenance of energy homeostasis may require a close interaction between leptin and thyroid hormone. This study was performed to investigate the change in plasma leptin levels relating to short-term thyroid manipulation causing no significant change in body weight. METHODS: Hypothyroidism was induced by surgical thyroidectomy and hyperthyroidism by subcutaneous injection of 50 g of L-T3/100 g body weight/day, for 5 days, in 6~8 weeks old male Wistar rats. Body weights and food intakes were monitored daily until sacrifice. Plasma samples were collected, and the thyroid stimulating hormone (TSH), free triiodothyronine (T3) and leptin levels measured. The plasma leptin levels in rats with hypothyroidism and hyperthyroidism were compared with those of body weights at death and food intakes during the study, atched controls. RESULTS: The rats treated with L-T3 consumed equal amount of food as freely fed, rats but their final body weights were significantly lower (L-T3 treated 220.0 +/- 1.8 vs. freely fed 226.0 +/- 2.0 g, p<0.05). There was no difference in food intake during study, and final body weight, between the thyroidectomised rats and their paired controls (thyroidectomised 220.4 +/- 1.7 vs. paired 223.9 +/- 4.7 g, P=NS). Plasma leptin levels in the L-T3 treated rats were significantly lower than those in freely fed rats (L-T3 treated 1.7 +/- 0.1 vs. freely fed 4.8 +/- 0.2 ng/ml, p<0.005). Conversely, the thyroidectomised rats had higher plasma leptin levels, compared to those of their paired controls (thyroidectomised 4.8 +/- 0.3 vs. paired 1.7 +/- 0.1 ng/ml, p<0.005). CONCLUSION: The Plasma leptin levels in the rats were decreased by short term hyperthyroidism, while they were increased by short term hypothyroidism. These findings suggest that thyroid hormones may affect the production or secretion of leptin

Author index